A clinical dietician with the Division of Gastroenterology, Hepatology and Nutrition at Children's Hospital of Philadelphia shares some tips to help families.

CHOP researchers have shown that NSAIDs disrupt epithelial cells in the colon and sensitize them to C. difficile toxins by perturbing cell mitochondria.

Researchers from Children’s Hospital of Philadelphia (CHOP) confirmed that “mini-intestines” generated from patient tissue samples and grown in a lab can accurately replicate certain features of Crohn’s disease, which will allow them to study the epithelium, the thin layer of cells lining the intestine, that is broken down in patients with inflammatory bowel disease. 

$4 million gift from the Escoll-Lubeck Charitable Foundation will support innovative and high-quality care to children with feeding and swallowing disorders and their families.

Very early onset inflammatory bowel disease was virtually unheard of just a decade ago. Today, a variety of personalized therapies exist, and potential curative gene therapies are on the horizon.

Continued surveillance after pancreatic solid pseudopapillary tumor and pancreatic insufficiency is important – even after treatment.

When rumination and gastroparesis collide in patients at Children’s Hospital of Philadelphia, a personalized treatment plan is developed.

Two recent studies show dupilumab improves eosinophilic esophagitis symptoms and pathology for adolescents and young adults.

Researchers from CHOP and Penn are working to perfect 3D models of GI disease and create more personalized treatments for patients.

Regional and local differences in the diagnosis and treatment of celiac disease affects outcomes for youth.